Literature DB >> 15614147

Early accumulation of interferon-gamma in grafts tolerized by donor-specific blood transfusion: friend or enemy?

Hiroaki Kitade1, Masaru Kawai, Takaaki Koshiba, Annapaula Giulietti, Lut Overbergh, Omer Rutgeerts, Dirk Valckx, Mark Waer, Chantal Mathieu, Jacques Pirenne.   

Abstract

BACKGROUND: We previously documented an early (day-2) interferon (IFN)-gamma accumulation in cardiac allografts of rats made tolerant by donor-specific blood transfusion (DSBT) but not in rejecting controls. This contrasted with the IFN-gamma peak seen later (day 5) in rejecting but not in tolerant rats.
METHODS: To further examine the role of early intragraft IFN-gamma in DSBT-induced tolerance, we studied whether IFN-gamma up-regulation correlates with the magnitude of the DSBT effect and how IFN-gamma is influenced by interventions abrogating tolerance.
RESULTS: The protective effect of DSBT depended upon the timing of administration: day-12 DSBT induced indefinite graft survival; day-6 DSBT gave a moderate, and day-0 DSBT, no graft prolongation. IFN-gamma up-regulation correlated with the DSBT effect: it was maximal after day-12 DSBT, intermediate after day-6 DSBT, and absent after day-0 DSBT. Tolerant splenocytes transferred tolerance into naive rats in a donor-specific manner, indicating that alloantigen-specific regulatory cells operate. Thymectomy prevented regulatory cells development, caused further amplification of intragraft IFN-gamma, and led to rejection, although graft survival was still prolonged.
CONCLUSIONS: Day 2 intragraft IFN-gamma correlates with the DSBT protective effect. Thymectomy abrogates DSBT-induced tolerance, prevents regulatory cell development, and paradoxically causes further accumulation of intragraft IFN-gamma. These data indicate that DSBT has a stimulatory and a (thymus-dependent) inhibitory effect on early intragraft IFN-gamma. Intragraft IFN-gamma is beneficial, providing it occurs early and remains moderate. The role of intragraft IFN-gamma in tolerance and rejection depends upon the timing and the degree of production and perhaps the type of IFN-gamma producing cells (regulatory or effector).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614147     DOI: 10.1097/01.tp.0000147788.23922.5b

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

Review 1.  Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants.

Authors:  Faisal Khan; Swati Agrawal; Suraksha Agrawal
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Host-based Th2 cell therapy for prolongation of cardiac allograft viability.

Authors:  Shoba Amarnath; Hao Chen; Jason E Foley; Carliann M Costanzo; Joel D Sennesh; Michael A Solomon; Daniel H Fowler
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

3.  Pin1 modulates the type 1 immune response.

Authors:  Stephane Esnault; Ruedi K Braun; Zhong-Jian Shen; Zhuzai Xiang; Erika Heninger; Robert B Love; Matyas Sandor; James S Malter
Journal:  PLoS One       Date:  2007-02-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.